

Angiogenesis: A Key Target in Oncology

Angiogenesis: A Key Target in Oncology

Barcelona, Spain

Friday 28 - Saturday 29 April, 2006

Course Objectives

This course will provide the background for oncologists to understand the basic science and the clinical achievements in angiogenesis related cancer therapy.

This is intended to be a practice-oriented course, helping decision-making processes for the clinician. Participants will have an opportunity to discuss patient case studies and interact with experts, as well as receive updates on the latest data and advances in this field.

This course will be submitted for approval for CME by ACOE and if approved will also be AMA Category Credit CME approved. Approval where needed by National CME organizations can also be requested.

Each participant will receive a certificate of attendance stating that he/she attended the entire course. The certificate of attendance will be distributed only at the end of the meeting, after a learning assessment test.

Course Organizer

ETICHO
(European Training in Clinical Hematology and Oncology)
info@eticho.org

Target Audience

Physicians and other Healthcare professionals

Official Language

English - no simultaneous translation will be available

Support from
Roche and Medigene

Chairmen

E. van Cutsem & G. Gasparini

Scientific Course Coordinator

M. Aapro

The field of angiogenesis has evolved from theory to practical clinical application. The initial successes promise that this area will become very important for cancer patient care. There are many questions that will need evaluation, and EORTC is looking forward to these developments. We wish great success to this meeting, organized in collaboration with several distinguished members of EORTC.

Prof. F. Meunier and Prof. A. Eggermont

Venue

Hotel Hilton Diagonal Mar
Passeig del Taulat 262-264
08019 Barcelona, Spain

Auspices of UICC are requested.

In cooperation with EORTC
 **EORTC**
European Organisation for Research
and Treatment of Cancer

Angiogenesis: A Key Target in Oncology

FRIDAY APRIL 28, 2006

Registration opens at 10:00 am

Lunch buffet available from 12:00 noon

Welcome

13:30 Welcome & Introduction

E. van Cutsem,
G. Gasparini & M. Aapro

Opening Talk

13:35 - 14:05 What is Angiogenesis in Relation to Cancer

G. Breier

Keynote Address

14:05 - 14:35 Developing Bevacizumab

N. Ferrara

Session I Clinically Relevant Basic Data on Angiogenesis

Chairs: K. Alitalo & L. Ellis

14:40 - 15:10 Understanding the Biology of Angiogenesis, Part I

K. Alitalo

15:10 - 15:40 Understanding the Biology of Angiogenesis, Part II

L. Ellis

15:40 - 16:10 Determining VEGF, VEGFR: What Helps the Clinician in Deciding to Use Anti-Angiogenesis Agents?

W.J.P. Steward

16:10 - 16:30 Coffee Break

Session II Angiogenesis and the Oncologist

Chair: W.J.P. Steward

16:30 - 17:00 Imaging and Angiogenesis - Are There Clinically Useful Clinical Strategies: The Role of Ultrasound

N. Lassau

17:00 - 17:30 Imaging and Angiogenesis - Are There Clinically Useful Clinical Strategies: The Role of PET, CT and MRI

G. Jayson

17:30 Closure of the Day

20:00 Buses depart from hotel lobby to Gala Dinner

SATURDAY APRIL 29, 2006

Session III Angiogenesis: Clinical Usage

08:00 - 08:30 Clinical Management of Anti-Angiogenesis Agents

H. Pinedo, Amsterdam

Session IV Today and Tomorrow, Part I

Chairs: E. van Cutsem & K. Miller

08:30 - 09:30 Anti-Angiogenic Therapy in the Treatment of Colorectal Cancer - Current Status and Opportunities: a State-of-the-art Lecture, followed by a Lecture on Anti-Angiogenic Drugs and Their Results

E. van Cutsem & D. Haller

09:30 - 10:30 Anti-Angiogenic Therapy in the Treatment of Breast Cancer - Current Status and Opportunities: a State-of-the-art Lecture, followed by a Lecture on Anti-Angiogenic Drugs and Their Results

J. Bergh & K. Miller

10:30 - 11:00 Coffee Break

Session V Today and Tomorrow, Part II

Chairs: G. Scagliotti & A. Awada

11:00 - 12:00 Anti-Angiogenic Therapy in the Treatment of Lung Cancer - Current Status and Opportunities: a State-of-the-art Lecture, Followed by a Lecture on Anti-Angiogenic Drugs and Their Results

G. Scagliotti & G. Gasparini

12:00 - 12:20 Anti-Angiogenic Drugs - Different Types, Different Targets: Really Different?

J.P. Armand

12:20 - 12:40 Anti-Angiogenesis Drugs and Prostate: Really Promising?

J. Bellmunt

12:40 - 13:00 Gastric Cancer: How to Position Anti-Angiogenic Drugs

J. Tabernero

13:00 - 13:20 Positioning Anti-angiogenesis Drugs and Other Agents in Renal Cell Cancer Treatment

A. Awada

13:20 - 13:40 Learning Assessments: attendees to fill in their evaluation forms and answer 15 questions based on the course. Certificates will be given ONLY after forms are completed.

13:40 - 14:30 Lunch buffet and certificate delivery

Presentations during the sessions I-III are preceded and followed by one interactive question using a keypad